Cargando…

Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET

PURPOSE: Measurement of heterogeneity in (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) images is reported to improve tumour phenotyping and response assessment in a number of cancers. We aimed to determine whether measurements of (18)F-FDG heterogeneity could improve differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Gary J. R., Lovat, Eitan, Siddique, Muhammad, Goh, Vicky, Ferner, Rosalie, Warbey, Victoria S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644685/
https://www.ncbi.nlm.nih.gov/pubmed/28589254
http://dx.doi.org/10.1007/s00259-017-3733-1
_version_ 1783271772351627264
author Cook, Gary J. R.
Lovat, Eitan
Siddique, Muhammad
Goh, Vicky
Ferner, Rosalie
Warbey, Victoria S.
author_facet Cook, Gary J. R.
Lovat, Eitan
Siddique, Muhammad
Goh, Vicky
Ferner, Rosalie
Warbey, Victoria S.
author_sort Cook, Gary J. R.
collection PubMed
description PURPOSE: Measurement of heterogeneity in (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) images is reported to improve tumour phenotyping and response assessment in a number of cancers. We aimed to determine whether measurements of (18)F-FDG heterogeneity could improve differentiation of benign symptomatic neurofibromas from malignant peripheral nerve sheath tumours (MPNSTs). METHODS: (18)F-FDG PET data from a cohort of 54 patients (24 female, 30 male, mean age 35.1 years) with neurofibromatosis-1 (NF1), and clinically suspected malignant transformation of neurofibromas into MPNSTs, were included. Scans were performed to a standard clinical protocol at 1.5 and 4 h post-injection. Six first-order [including three standardised uptake value (SUV) parameters], four second-order (derived from grey-level co-occurrence matrices) and four high-order (derived from neighbourhood grey-tone difference matrices) statistical features were calculated from tumour volumes of interest. Each patient had histological verification or at least 5 years clinical follow-up as the reference standard with regards to the characterisation of tumours as benign (n = 30) or malignant (n = 24). RESULTS: There was a significant difference between benign and malignant tumours for all six first-order parameters (at 1.5 and 4 h; p < 0.0001), for second-order entropy (only at 4 h) and for all high-order features (at 1.5 h and 4 h, except contrast at 4 h; p < 0.0001–0.047). Similarly, the area under the receiver operating characteristic curves was high (0.669–0.997, p < 0.05) for the same features as well as 1.5-h second-order entropy. No first-, second- or high-order feature performed better than maximum SUV (SUVmax) at differentiating benign from malignant tumours. CONCLUSIONS: (18)F-FDG uptake in MPNSTs is higher than benign symptomatic neurofibromas, as defined by SUV parameters, and more heterogeneous, as defined by first- and high-order heterogeneity parameters. However, heterogeneity analysis does not improve on SUVmax discriminative performance.
format Online
Article
Text
id pubmed-5644685
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-56446852017-10-18 Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET Cook, Gary J. R. Lovat, Eitan Siddique, Muhammad Goh, Vicky Ferner, Rosalie Warbey, Victoria S. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Measurement of heterogeneity in (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) images is reported to improve tumour phenotyping and response assessment in a number of cancers. We aimed to determine whether measurements of (18)F-FDG heterogeneity could improve differentiation of benign symptomatic neurofibromas from malignant peripheral nerve sheath tumours (MPNSTs). METHODS: (18)F-FDG PET data from a cohort of 54 patients (24 female, 30 male, mean age 35.1 years) with neurofibromatosis-1 (NF1), and clinically suspected malignant transformation of neurofibromas into MPNSTs, were included. Scans were performed to a standard clinical protocol at 1.5 and 4 h post-injection. Six first-order [including three standardised uptake value (SUV) parameters], four second-order (derived from grey-level co-occurrence matrices) and four high-order (derived from neighbourhood grey-tone difference matrices) statistical features were calculated from tumour volumes of interest. Each patient had histological verification or at least 5 years clinical follow-up as the reference standard with regards to the characterisation of tumours as benign (n = 30) or malignant (n = 24). RESULTS: There was a significant difference between benign and malignant tumours for all six first-order parameters (at 1.5 and 4 h; p < 0.0001), for second-order entropy (only at 4 h) and for all high-order features (at 1.5 h and 4 h, except contrast at 4 h; p < 0.0001–0.047). Similarly, the area under the receiver operating characteristic curves was high (0.669–0.997, p < 0.05) for the same features as well as 1.5-h second-order entropy. No first-, second- or high-order feature performed better than maximum SUV (SUVmax) at differentiating benign from malignant tumours. CONCLUSIONS: (18)F-FDG uptake in MPNSTs is higher than benign symptomatic neurofibromas, as defined by SUV parameters, and more heterogeneous, as defined by first- and high-order heterogeneity parameters. However, heterogeneity analysis does not improve on SUVmax discriminative performance. Springer Berlin Heidelberg 2017-06-07 2017 /pmc/articles/PMC5644685/ /pubmed/28589254 http://dx.doi.org/10.1007/s00259-017-3733-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Cook, Gary J. R.
Lovat, Eitan
Siddique, Muhammad
Goh, Vicky
Ferner, Rosalie
Warbey, Victoria S.
Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
title Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
title_full Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
title_fullStr Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
title_full_unstemmed Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
title_short Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
title_sort characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)f-fdg pet
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644685/
https://www.ncbi.nlm.nih.gov/pubmed/28589254
http://dx.doi.org/10.1007/s00259-017-3733-1
work_keys_str_mv AT cookgaryjr characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet
AT lovateitan characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet
AT siddiquemuhammad characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet
AT gohvicky characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet
AT fernerrosalie characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet
AT warbeyvictorias characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet